Cano-Pumarega I - Search Results

1

Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).

Garcia-Borreguero D, Cano-Pumarega I, Marulanda R. Garcia-Borreguero D, et al. Sleep Med Rev. 2018 Oct;41:50-60. doi: 10.1016/j.smrv.2018.01.001. Epub 2018 Jan 9. Sleep Med Rev. 2018. PMID: 29602660 Review.

2

New concepts in the management of restless legs syndrome.

Garcia-Borreguero D, Cano-Pumarega I. Garcia-Borreguero D, et al. BMJ. 2017 Feb 27;356:j104. doi: 10.1136/bmj.j104. BMJ. 2017. PMID: 28242627 Review.

3

Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis.

Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferré S. Garcia-Borreguero D, et al. Sleep Med. 2018 May;45:94-97. doi: 10.1016/j.sleep.2018.02.002. Epub 2018 Feb 24. Sleep Med. 2018. PMID: 29680437 Clinical Trial.

4

Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment.

Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Garcia-Borreguero D, et al. Sleep Med. 2019 Mar;55:74-80. doi: 10.1016/j.sleep.2018.11.025. Epub 2018 Dec 26. Sleep Med. 2019. PMID: 30772697 Free article. Clinical Trial.

5

Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.

Wanner V, Garcia Malo C, Romero S, Cano-Pumarega I, García-Borreguero D. Wanner V, et al. Adv Pharmacol. 2019;84:187-205. doi: 10.1016/bs.apha.2019.02.003. Epub 2019 Mar 14. Adv Pharmacol. 2019. PMID: 31229171 Review.

6

Treating restless legs syndrome in the context of sleep disordered breathing comorbidity.

Romero-Peralta S, Cano-Pumarega I, Garcia-Malo C, Agudelo Ramos L, García-Borreguero D. Romero-Peralta S, et al. Eur Respir Rev. 2019 Oct 1;28(153):190061. doi: 10.1183/16000617.0061-2019. Print 2019 Sep 30. Eur Respir Rev. 2019. PMID: 31578212 Free PMC article. Review.

7

Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome.

Garcia-Malo C, Wanner V, Miranda C, Romero Peralta S, Agudelo L, Cano-Pumarega I, Granizo JJ, Garcia-Borreguero D. Garcia-Malo C, et al. Sleep Med. 2020 Feb;66:123-129. doi: 10.1016/j.sleep.2019.09.020. Epub 2019 Oct 30. Sleep Med. 2020. PMID: 31875533

8

Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome.

Romero-Peralta S, Cano-Pumarega I, García-Borreguero D. Romero-Peralta S, et al. Chest. 2020 Sep;158(3):1218-1229. doi: 10.1016/j.chest.2020.03.035. Epub 2020 Apr 2. Chest. 2020. PMID: 32247713 Review.

9

Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting.

Garcia-Malo C, Miranda C, Novo Ponte S, Romero Peralta S, Cano-Pumarega I, Boi S, Martínez Vidal V, Anguizola S, Botta L, Garcia-Borreguero D. Garcia-Malo C, et al. Sleep Med. 2020 Oct;74:48-55. doi: 10.1016/j.sleep.2020.06.002. Epub 2020 Jun 10. Sleep Med. 2020. PMID: 32841843

10

Restless Legs Syndrome - Clinical Features.

Garcia-Malo C, Romero-Peralta S, Cano-Pumarega I. Garcia-Malo C, et al. Sleep Med Clin. 2021 Jun;16(2):233-247. doi: 10.1016/j.jsmc.2021.02.002. Epub 2021 Apr 24. Sleep Med Clin. 2021. PMID: 33985650 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters